Retatrutide (development code LY-3437943) is a synthetic peptide developed by Eli Lilly and Company designed to act simultaneously on three hormone-receptor pathways: GLP-1 (glucagonlike peptide-1) GIP (glucosedependent insulinotropic polypeptide) Glucagon receptor (GCG) nejm.org Put simply: it takes the mechanism of todays weight-loss injections and adds an extra dimension of hormonal stimulation, with the aim of significantly greater weight-loss outcomes
Unlike Ozempic, which works through GLP-1 alone, retatrutide adds GIP and glucagon receptor activity on top of the GLP-1 backbone
Biochem Biophys Res Commun 223: 624-632, 1996
A diferencia de otros pptidos, como el conocido Tirzepatide, el Retatrutide combina tres mecanismos de accin nicos que lo hacen especialmente efectivo en ciertos casos
doi: 10.1074/jbc.M112.362632 155 YiLSwensenACQianWJ
The pharmacokinetics of peptide-based medications, including how they distribute through tissue and how quickly they are cleared, are influenced by body mass
